via ft.com
But even if overhauling R&D boosts innovation, the benefits for some companies will not come fast enough. “There’s a lot of talk about the patent cliff,” says Nils Behnke, a partner with Bain, the consultancy. “The problem could maybe have been solved 10 years ago. But now there is going to be a gap.”
He estimates that $100bn (€79bn, £67bn) in sales from medicines will be lost in the next five years as intellectual property protections expire, while the value of drugs in development in the industry’s collective pipeline that could be launched during that period are worth just $30bn.
No comments:
Post a Comment